keyword
MENU ▼
Read by QxMD icon Read
search

Artificial pancreas

keyword
https://www.readbyqxmd.com/read/28098839/continuous-glucose-monitoring-enables-the-detection-of-losses-in-infusion-set-actuation-lisas
#1
Daniel P Howsmon, Faye Cameron, Nihat Baysal, Trang T Ly, Gregory P Forlenza, David M Maahs, Bruce A Buckingham, Juergen Hahn, B Wayne Bequette
Reliable continuous glucose monitoring (CGM) enables a variety of advanced technology for the treatment of type 1 diabetes. In addition to artificial pancreas algorithms that use CGM to automate continuous subcutaneous insulin infusion (CSII), CGM can also inform fault detection algorithms that alert patients to problems in CGM or CSII. Losses in infusion set actuation (LISAs) can adversely affect clinical outcomes, resulting in hyperglycemia due to impaired insulin delivery. Prolonged hyperglycemia may lead to diabetic ketoacidosis-a serious metabolic complication in type 1 diabetes...
January 15, 2017: Sensors
https://www.readbyqxmd.com/read/28097553/-pumps-sensors-and-the-dream-of-the-artificial-pancreas-a-clinical-update-to-modern-technologies-in-diabetes
#2
REVIEW
Bernhard Gehr
No abstract text is available yet for this article.
January 2017: MMW Fortschritte der Medizin
https://www.readbyqxmd.com/read/28094472/outpatient-60-hour%C3%A2-day-and-night%C3%A2-glucose-control-with-dual-hormone%C3%A2-artificial-pancreas-single-hormone-artificial-pancreas-%C3%A2-or-sensor-augmented-pump-therapy-in-adults-with%C3%A2-type-1-diabetes-an-open-label-%C3%A2-randomised-crossover-controlled-trial
#3
Ahmad Haidar, Virginie Messier, Laurent Legault, Martin Ladouceur, Rémi Rabasa-Lhoret
AIMS: To assess whether the dual-hormone (insulin and glucagon) artificial pancreas reduces hypoglycemia compared to the single-hormone (insulin alone) artificial pancreas in outpatient settings during the day and night. MATERIAL AND METHODS: In a randomized, three-way, crossover trial, we compared the dual-hormone artificial pancreas, the single-hormone artificial pancreas, and sensor-augmented pump therapy (control) in 23 adults with type 1 diabetes. Each intervention was applied from 08 h00 Day 1 to 20 h00 Day 3 (60 hours) in outpatient free-living conditions...
January 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28094137/the-artificial-pancreas-ready-for-prime-time
#4
J Hans DeVries
No abstract text is available yet for this article.
January 13, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28092515/towards-a-run-to-run-adaptive-artificial-pancreas-in-silico-results
#5
Chiara Toffanin, Roberto Visentin, Mirko Messori, Federico Di Palma, Lalo Magni, Claudio Cobelli
: Contemporary and future outpatient long-term artificial pancreas (AP) studies need to cope with the well-known large intra- and inter-day glucose variability occurring in type 1 diabetic (T1D) subjects. Here we propose an adaptive Model Predictive Control (MPC) strategy to account for it and test it in silico. METHODS: A Run-to-Run (R2R) approach adapts the subcutaneous basal insulin delivery during the night and the carbohydrate-to-insulin ratio (CR) during the day, based on some performance indices calculated from subcutaneous continuous glucose sensor data...
January 11, 2017: IEEE Transactions on Bio-medical Engineering
https://www.readbyqxmd.com/read/28060528/-learning-can-improve-the-blood-glucose-control-performance-for-type-1-diabetes-mellitus
#6
Youqing Wang, Jinping Zhang, Fanmao Zeng, Na Wang, Xiaoping Chen, Bo Zhang, Dong Zhao, Wenying Yang, Claudio Cobelli
BACKGROUND: A learning-type artificial pancreas has been proposed to exploit the repetitive nature in the blood glucose dynamics. We clinically evaluated the efficacy of the learning-type artificial pancreas. METHODS: We conducted a pilot clinical study in 10 participants of mean age 36.1 years (standard deviation [SD] 12.7; range 16-58) with type 1 diabetes. Each trial was conducted for eight consecutive mornings. The first two mornings were open-loop to obtain the individualized parameters...
January 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28055224/in-home-closed-loop-control-for-artificial-pancreas-patient-and-provider-perspective
#7
Laya Ekhlaspour, David M Maahs
No abstract text is available yet for this article.
January 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27982707/feasibility-of-long-term-closed-loop-control-a-multicenter-6-month-trial-of-24-7-automated-insulin-delivery
#8
Boris Kovatchev, Peiyao Cheng, Stacey M Anderson, Jordan E Pinsker, Federico Boscari, Bruce A Buckingham, Francis J Doyle, Korey K Hood, Sue A Brown, Marc D Breton, Daniel Chernavvsky, Wendy C Bevier, Paige K Bradley, Daniela Bruttomesso, Simone Del Favero, Roberta Calore, Claudio Cobelli, Angelo Avogaro, Trang T Ly, Satya Shanmugham, Eyal Dassau, Craig Kollman, John W Lum, Roy W Beck
BACKGROUND: In the past few years, the artificial pancreas-the commonly accepted term for closed-loop control (CLC) of blood glucose in diabetes-has become a hot topic in research and technology development. In the summer of 2014, we initiated a 6-month trial evaluating the safety of 24/7 CLC during free-living conditions. RESEARCH DESIGN AND METHODS: Following an initial 1-month Phase 1, 14 individuals (10 males/4 females) with type 1 diabetes at three clinical centers in the United States and one in Italy continued with a 5-month Phase 2, which included 24/7 CLC using the wireless portable Diabetes Assistant (DiAs) developed at the University of Virginia Center for Diabetes Technology...
January 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27956473/diabetes-induced-by-gain-of-function-mutations-in-the-kir6-1-subunit-of-the-katp-channel
#9
Maria S Remedi, Jonathan B Friedman, Colin G Nichols
Gain-of-function (GOF) mutations in the pore-forming (Kir6.2) and regulatory (SUR1) subunits of KATP channels have been identified as the most common cause of human neonatal diabetes mellitus. The critical effect of these mutations is confirmed in mice expressing Kir6.2-GOF mutations in pancreatic β cells. A second KATP channel pore-forming subunit, Kir6.1, was originally cloned from the pancreas. Although the prominence of this subunit in the vascular system is well documented, a potential role in pancreatic β cells has not been considered...
January 2017: Journal of General Physiology
https://www.readbyqxmd.com/read/27956115/future-perspectives-in-adult-stem-cell-turnover-implications-for-endocrine-physiology-and-disease
#10
Clara V Alvarez, Fernando Oroz-Gonjar, Montserrat Garcia-Lavandeira
No abstract text is available yet for this article.
December 9, 2016: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/27942106/enhanced-model-predictive-control-empc-strategy-for-automated-glucose-control
#11
Joon Bok Lee, Eyal Dassau, Ravi Gondhalekar, Dale E Seborg, Jordan E Pinsker, Francis J Doyle
Development of an effective artificial pancreas (AP) controller to deliver insulin autonomously to people with type 1 diabetes mellitus is a difficult task. In this paper, three enhancements to a clinically validated AP model predictive controller (MPC) are proposed that address major challenges facing automated blood glucose control, and are then evaluated by both in silico tests and clinical trials. First, the core model of insulin-blood glucose dynamics utilized in the MPC is expanded with a medically inspired personalization scheme to improve controller responses in the face of inter- and intra-individual variations in insulin sensitivity...
November 23, 2016: Industrial & Engineering Chemistry Research
https://www.readbyqxmd.com/read/27941663/continuous-glucose-monitoring-sensors-past-present-and-future-algorithmic-challenges
#12
Andrea Facchinetti
Continuous glucose monitoring (CGM) sensors are portable devices that allow measuring and visualizing the glucose concentration in real time almost continuously for several days and are provided with hypo/hyperglycemic alerts and glucose trend information. CGM sensors have revolutionized Type 1 diabetes (T1D) management, improving glucose control when used adjunctively to self-monitoring blood glucose systems. Furthermore, CGM devices have stimulated the development of applications that were impossible to create without a continuous-time glucose signal, e...
December 9, 2016: Sensors
https://www.readbyqxmd.com/read/27918508/the-artificial-pancreas-gets-real
#13
Ellen Sheng
No abstract text is available yet for this article.
October 18, 2016: Scientific American
https://www.readbyqxmd.com/read/27913173/hacking-diabetes-diy-artificial-pancreas-systems
#14
Conor Farrington
No abstract text is available yet for this article.
November 29, 2016: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/27912033/human-factor-considerations-for-artificial-pancreas-research
#15
Linda A Gonder-Frederick, Jesse H Grabman, Jaclyn A Shepard
No abstract text is available yet for this article.
December 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27877104/sweet-taste-receptor-serves-to-activate-glucose-and-leptin-responsive-neurons-in-the-hypothalamic-arcuate-nucleus-and-participates-in-glucose-responsiveness
#16
Daisuke Kohno, Miho Koike, Yuzo Ninomiya, Itaru Kojima, Tadahiro Kitamura, Toshihiko Yada
The hypothalamic feeding center plays an important role in energy homeostasis. In the feeding center, whole-body energy signals including hormones and nutrients are sensed, processed, and integrated. As a result, food intake and energy expenditure are regulated. Two types of glucose-sensing neurons exist in the hypothalamic arcuate nucleus (ARC): glucose-excited neurons and glucose-inhibited neurons. While some molecules are known to be related to glucose sensing in the hypothalamus, the mechanisms underlying glucose sensing in the hypothalamus are not fully understood...
2016: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/27852685/evaluating-the-experience-of-children-with-type-1-diabetes-and-their-parents-taking-part-in-an-artificial-pancreas-clinical-trial-over-multiple-days-in-a-diabetes-camp-setting
#17
Alda Troncone, Riccardo Bonfanti, Dario Iafusco, Ivana Rabbone, Alberto Sabbion, Riccardo Schiaffini, Alfonso Galderisi, Marco Marigliano, Novella Rapini, Andrea Rigamonti, Davide Tinti, Valeria Vallone, Angela Zanfardino, Federico Boscari, Simone Del Favero, Silvia Galasso, Giordano Lanzola, Mirko Messori, Federico Di Palma, Roberto Visentin, Roberta Calore, Yenny Leal, Lalo Magni, Eleonora Losiouk, Daniel Chernavvsky, Silvana Quaglini, Claudio Cobelli, Daniela Bruttomesso
OBJECTIVE: To explore the experiences of children with type 1 diabetes and their parents taking part in an artificial pancreas (AP) clinical trial during a 7-day summer camp. RESEARCH DESIGN AND METHODS: A semistructured interview, composed of 14 questions based on the Technology Acceptance Model, was conducted at the end of the clinical trial. Participants also completed the Diabetes Treatment Satisfaction Questionnaire (DTSQ, parent version) and the AP Acceptance Questionnaire...
December 2016: Diabetes Care
https://www.readbyqxmd.com/read/27836235/closed-loop-insulin-delivery-in-inpatients-with-type-2-diabetes-a-randomised-parallel-group-trial
#18
Hood Thabit, Sara Hartnell, Janet M Allen, Andrea Lake, Malgorzata E Wilinska, Yue Ruan, Mark L Evans, Anthony P Coll, Roman Hovorka
BACKGROUND: We assessed whether fully closed-loop insulin delivery (the so-called artificial pancreas) is safe and effective compared with standard subcutaneous insulin therapy in patients with type 2 diabetes in the general ward. METHODS: For this single-centre, open-label, parallel-group, randomised controlled trial, we enrolled patients aged 18 years or older with type 2 diabetes who were receiving insulin therapy. Patients were recruited from general wards at Addenbrooke's Hospital, Cambridge, UK...
November 8, 2016: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/27784829/coordination-or-collision-the-intersection-of-diabetes-care-cybersecurity-and-cloud-based-computing
#19
Scott Thiel, Jennifer Mitchell, Jim Williams
Diagnosis and treatment of diabetes changed little from the Middle Ages through the early 19th century, when the first chemical test for the condition was developed. In the 20th century, advances in diabetes management gained momentum with home-use diagnostic devices and mass-produced insulin. In the 21st century, technological developments around diabetes are advancing so rapidly that a small, discrete system of medical devices that serve as an artificial pancreas are now possible. In this article, we assert that medical device interoperability and cyber security are necessary preconditions for safe, effective, and reliable widespread use of the artificial pancreas system...
October 26, 2016: Journal of Diabetes Science and Technology
https://www.readbyqxmd.com/read/27749113/impact-of-meal-constituents-on-artificial-pancreas-algorithms
#20
Enrique Campos-Náñez, Boris P Kovatchev
No abstract text is available yet for this article.
October 2016: Diabetes Technology & Therapeutics
keyword
keyword
44204
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"